דומיטור וטרינרי ישראל - עברית - Ministry of Health

דומיטור וטרינרי

pfizer pharmaceuticals israel ltd - medetomidine hydrochloride 1 mg/ml - solution for injection - dogs:for restraint, sedation and analgesia associated with clinical examinations and procedures, minor surgery and pre-anaesthesia.as a premedicant before thiopentone, halothane general anaesthesia and as a premedicant before general anaesthesia with propofol.cats:for restraint and sedation.in combination with ketamine for induction of general anaesthesia prior to surgical procedures.

אטוסיבן - פרינג ישראל - עברית - Ministry of Health

אטוסיבן - פרינג

ferring pharmaceuticals ltd - atosiban - solution for injection - atosiban 7.5 mg/ml - atosiban - atosiban - atosiban is indicated to delay imminent pre-term birth in pregnant women with: - regular uterine contractions of at least 30 seconds duration at a rate of 4 or more per 30 minutes - a cervical dilation of 1 to 3 cm (0-3 for iparas) and effacement of 50 % or more - age: 18 years and above - a gestational age from 24 until 33 completed weeks - a normal foetal heart rate.

נוטרופין איי.קיו 10 מ"ג/2 מ"ל ישראל - עברית - Ministry of Health

נוטרופין איי.קיו 10 מ"ג/2 מ"ל

medison pharma ltd - somatropin 5 mg / 1 ml - solution for injection - somatropin - 1. long-term treatment of children with growth failure due to inadequateendogenous growth hormone secretion.2. long-term treatment of growth failure associated with turner syndrome. 3. treatment of prepubertal children with growth failure associated with chronic renal insufficiency up to the time of renal transplantation. 4. replacement of endogenous growth hormone in adults with growth hormone deficiency or either childhood or adult-onset etiology. growth hormone deficiency of either childhood or adult-onset etiology. growth hormone deficiency should be confirmed appropriately prior to treatment.

רקורמון 2000 IU ישראל - עברית - Ministry of Health

רקורמון 2000 iu

roche pharmaceuticals (israel) ltd - epoetin beta 2000 iu / 0.3 ml - solution for injection - erythropoietin - treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. treatment of symptomatic renal anemia in patients not yet undergoing dialysis. increasing the yield of autologous blood from patients in a pre-donation program. its use in this indication must be balanced against the reported increased risk of thromboembolic events. treatment should only be given to patients with moderate anemia (hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). treatment of anemia in adult patients with solid tumors and treated with platinum-based chemotherapy prone to induce anemia (cisplatin 75 mg/m2/cycle carboplatin: 350 mg/m2/cycle). treatment of anemia in adult patients with multiple myeloma low grade non-hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative

רקורמון IU 3000 ישראל - עברית - Ministry of Health

רקורמון iu 3000

roche pharmaceuticals (israel) ltd - epoetin beta 3000 iu / 0.3 ml - solution for injection - erythropoietin - treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. treatment of symptomatic renal anemia in patients not yet undergoing dialysis. increasing the yield of autologous blood from patients in a pre-donation program. its use in this indication must be balanced against the reported increased risk of thromboembolic events. treatment should only be given to patients with moderate anemia (hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). treatment of anemia in adult patients with solid tumors and treated with platinum-based chemotherapy prone to induce anemia (cisplatin 75 mg/m2/cycle carboplatin: 350 mg/m2/cycle). treatment of anemia in adult patients with multiple myeloma low grade non-hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative

סדקסילן וטרינרי ישראל - עברית - Ministry of Health

סדקסילן וטרינרי

abic veterinary products ltd - xylazine as hydrochloride 20 mg/ml - solution for injection - sedation and pre-medication (cats and dogs) for general anaesthesia in cats, dogs, horses, cattle, sheep and goats.

פרקסיפרין 0.4 מ"ל/ 3800 IU AXA ישראל - עברית - Ministry of Health

פרקסיפרין 0.4 מ"ל/ 3800 iu axa

glaxo smith kline (israel) ltd - nadroparin calcium 3800 iu / 0.4 ml - solution for injection - nadroparin - prophylactic treatment of venous thromboembolic disease during surgery for patients presenting with moderate or high risk. treatment of constituted deep vein thrombosis. prevention of coagulation in the extra corporeal circuit during heamodialysis. the prophylaxis of thromboembolic disorders in high risk medical patients (respiratory failure and/or respiratory infection and/or cardiac failure) hospitalised in intensive care unit.

פרקסיפרין 0.3 מ"ל / 2850 AXa IU ישראל - עברית - Ministry of Health

פרקסיפרין 0.3 מ"ל / 2850 axa iu

glaxo smith kline (israel) ltd - nadroparin calcium 2850 iu / 0.3 ml - solution for injection - nadroparin - prophylactic treatment of venous thromboembolic disease during surgery for patients presenting with moderate or high risk. treatment of constituted deep vein thrombosis. prevention of coagulation in the extra corporeal circuit during haemodialysis. the prophylaxis of thromboembolic disorders in high risk medical patients (respiratory failure and/or respiratory infection and/or cardiac failure) hospitalised in intensive care unit.

פרקסיפרין 0.6 מ"ל/ 5700 IU AXA ישראל - עברית - Ministry of Health

פרקסיפרין 0.6 מ"ל/ 5700 iu axa

glaxo smith kline (israel) ltd - nadroparin calcium 5700 iu / 0.6 ml - solution for injection - nadroparin - prophylactic treatment of venous thromboembolic disease during surgery for patients presenting with moderate or high risk. treatment of constituted deep vein thrombosis. prevention of coagulation in the extra corporeal circuit during haemodialysis. the prophylaxis of thromboembolic disorders in high risk medical patients (respiratory failure and/or respiratory infection and/or cardiac failure) hospitalised in intensive care unit.

פרקסיפרין 0.8 מ"ל/7600 IU AXa ישראל - עברית - Ministry of Health

פרקסיפרין 0.8 מ"ל/7600 iu axa

glaxo smith kline (israel) ltd - nadroparin calcium 7600 iu / 0.8 ml - solution for injection - nadroparin - prophylactic treatment of venous thromboembolic disease during surgery for patients presenting with moderate or high risk. treatment of constituted deep vein thrombosis. prevention of coagulation in the extra corporeal circuit during haemodialysis. the prophylaxis of thromboembolic disorders in high risk medical patients (respiratory failure and/or respiratory infection and/or cardiac failure) hospitalised in intensive care unit.